Roytberg GE1, Plotkin M2 and Sharkhun OO1*
1Pirogov Russian National Research Medical University, Moscow, Russia
2The Vivantes Institute for Nuclear Medicine, Berlin, Germany
*Corresponding Author: Roytberg GE, Pirogov Russian National Research Medical University, Moscow, Russia.
Received: March 14, 2022; Published: June 20, 2022
Despite the improvement of diagnostic methods and the introduction of prostate-specific antigen monitoring, the incidence of advanced forms of prostate cancer in Russia remains high. Long-term hormonal therapy often leads to tumor adaptation and further progression of the disease, the development of castrate-resistant prostate cancer, the complications of which significantly worsen the quality of life and adversely affect overall survival rates. Over the past 3 years along with the introduction into clinical practice of numerous drugs for the treatment of such forms of the disease, new types of palliative peptide receptor radionuclide therapy have been developed in particular, using the isotopes Lutetium-177, Radium-223, Actinium-225 etc. Currently therapy with 177Lu -PSMA is experimental in nature, as the drug has not yet been approved for clinical use by either European or American drug control agencies. However, the results of studies published to date are encouraging for the future clinical applications of 177Lu-PSMA therapy. The results of prospective studies conducted in the last 2-3 years will be crucial for the future of this method.
Citation: Roytberg GE., et al. “Prospects for the Clinical Use of Radionuclide Therapy for Castrate-resistant Metastatic Prostate Cancer with 177Lu-PSMA”.Acta Scientific Medical Sciences 6.7 (2022): 179-183.
Copyright: © 2022 Roytberg GE., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.